208 related articles for article (PubMed ID: 30614559)
1. Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab.
Komatsu-Fujii T; Nomura M; Otsuka A; Ishida Y; Doi K; Matsumoto S; Muto M; Kabashima K
J Dermatol; 2019 Jun; 46(6):e203-e204. PubMed ID: 30614559
[No Abstract] [Full Text] [Related]
2. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
Murer C; Kränzlin-Stieger P; French LE; Dummer R; Goldinger SM
Melanoma Res; 2017 Aug; 27(4):396-398. PubMed ID: 28410286
[TBL] [Abstract][Full Text] [Related]
4. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.
Reilley MJ; Bailey A; Subbiah V; Janku F; Naing A; Falchook G; Karp D; Piha-Paul S; Tsimberidou A; Fu S; Lim J; Bean S; Bass A; Montez S; Vence L; Sharma P; Allison J; Meric-Bernstam F; Hong DS
J Immunother Cancer; 2017; 5():35. PubMed ID: 28428884
[TBL] [Abstract][Full Text] [Related]
6. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
7. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma.
Sezen D; Patel RR; Tang C; Onstad M; Nagarajan P; Patel SP; Welsh JW; Lin LL
Gynecol Oncol; 2021 Jun; 161(3):645-652. PubMed ID: 33795130
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody.
Yamashita C; Otsuka A; Nomura M; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e92-e93. PubMed ID: 30199578
[No Abstract] [Full Text] [Related]
10. Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Cho J; Kim SY; Kim YJ; Sim MH; Kim ST; Kim NKD; Kim K; Park W; Kim JH; Jang KT; Lee J
Clin Transl Oncol; 2017 Oct; 19(10):1247-1252. PubMed ID: 28421416
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol.
Hirai I; Tanese K; Fukuda K; Fusumae T; Nakamura Y; Sato Y; Amagai M; Funakoshi T
Medicine (Baltimore); 2021 Dec; 100(49):e27832. PubMed ID: 34889232
[TBL] [Abstract][Full Text] [Related]
12. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Carreau NA; Pavlick AC
Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
15. Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study.
Wei X; Mao L; Chi Z; Sheng X; Cui C; Kong Y; Dai J; Wang X; Li S; Tang B; Lian B; Yan X; Bai X; Zhou L; Guo J; Si L
Oncol Res; 2019 Mar; 27(4):495-501. PubMed ID: 30075827
[TBL] [Abstract][Full Text] [Related]
16. Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.
Abdou Y; Kapoor A; Hamad L; Ernstoff MS
Medicine (Baltimore); 2019 Nov; 98(44):e17769. PubMed ID: 31689840
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
McKean M; Oba J; Ma J; Roth KG; Wang WL; Macedo MP; Carapeto FCL; Haydu LE; Siroy AE; Vo P; Hong DS; Eterovic AK; Patel KP; Bassett RL; Grimm EA; Lazar AJ; Woodman SE
J Invest Dermatol; 2019 Mar; 139(3):728-731. PubMed ID: 30798855
[No Abstract] [Full Text] [Related]
18. Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.
Broderick V; Waghorn K; Langabeer SE; Jeffers M; Cross NCP; Hayden PJ
Leuk Res; 2019 Feb; 77():28-29. PubMed ID: 30612056
[No Abstract] [Full Text] [Related]
19. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
Zhang H; Liang Z; Hu Y; Wang X; Wang B; Huang H
Leuk Lymphoma; 2018 Dec; 59(12):3018-3019. PubMed ID: 29616854
[No Abstract] [Full Text] [Related]
20. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
[No Abstract] [Full Text] [Related]
[Next] [New Search]
